News of the index components Russell 2000

Index

RUT

Market Closed - Nasdaq 03:35:13 01/06/2024 am IST			5-day change	1st Jan Change
2,070 ^PTS	+0.66%		+1.06%	+2.12%

31/05	FOR THE WEEK, THE S&P 500 FELL 0.48%, THE NASDAQ DECLINED 1.1%,…	RE
30/05	INmune Bio to Join Russell 3000 Index in July	MT

News of the index components

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Telsey Advisory Adjusts Price Target on Foot Locker to $27 From $26, Maintains Market Perform Rating FL	31/05	MT
Ameris Bank Ranked Top 10 Mortgage Provider ABCB	31/05	PR
EPlus Earns Spot on CRN's 2024 Solution Provider 500 List PLUS	31/05	PR
Chatham Lodging Trust Acquires Home2 Suites Phoenix Downtown CLDT	31/05	BU
TETRA TECHNOLOGIES, INC. TO PARTICIPATE IN THE STIFEL 2024 CROSS SECTOR INSIGHT CONFERENCE TTI	31/05	PR
Beacon Releases Annual Corporate Social Responsibility Report BECN	31/05	BU
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation NX	31/05	EQ
Safe Bulkers, Inc. Announces the Implementation of Integrated Management System in Compliance with DryBMS Standards SB	31/05	AQ
Feed One's Full-Year Profit Up 393% MPX	31/05	MT
Neogen to Participate in the 44th Annual William Blair Growth Stock Conference NEOG	31/05	AQ
American Software's Board Approves the Quarterly Cash Dividend AMSWA	31/05	AQ
Calix Delivers Industry's Only Integrated, High-Density Service Aggregation Portfolio So Broadband Providers Can Serve Highly Populated Regions and New Markets CALX	31/05	AQ
Hyperscience Named a Leader in Document Mining and Analytics Platforms Evaluation Report FORR	31/05	AQ
Transcript : Genesco Inc., Q1 2025 Earnings Call, May 31, 2024 GCO	31/05
Oppenheimer Initiates Coverage on Beazer Homes USA With Outperform Rating, $37 Price Target BZH	31/05	MT
William Blair Starts Federal Signal With Outperform Rating FSS	31/05	MT
Keefe Bruyette & Woods Trims MBIA's Price Target to $6.50 From $7.50, Maintains Market Perform Rating MBI	31/05	MT
B. Riley Raises Price Target on Dycom Industries to $205 From $172, Maintains Buy Rating DY	31/05	MT
Rosenblatt Starts Quad Graphics With Buy Rating QUAD	31/05	MT
ABM Named Among Barron’s 100 Most Sustainable Companies for Second Consecutive Year ABM	31/05	AQ
EGain Announces Increase to Stock Repurchase Program of $20 Million EGAN	31/05	AQ
Keefe, Bruyette & Woods Downgrades OceanFirst Financial to Market Perform From Outperform, Price Target at $18 OCFC	31/05	MT
Keefe, Bruyette & Woods Upgrades UMB Financial to Outperform From Market Perform With $98 Price Target UMBF	31/05	MT
PNM Resources Receives New Mexico Regulatory OK for 410 Megawatt Solar, Battery Expansion PNM	31/05	MT
Roth MKM Upgrades LeMaitre Vascular to Buy Rating With $100 Price Target LMAT	31/05	MT
Piper Sandler Upgrades Independent Bank to Overweight From Underweight IBTX	31/05	MT
Keefe, Bruyette & Woods Upgrades Heartland Financial USA to Outperform From Market Perform With $54 Price Target HTLF	31/05	MT
Keefe, Bruyette & Woods Upgrades Hancock Whitney to Outperform from Market Perform With $55 Price Target HWC	31/05	MT
Genesco: Fiscal Q1 Earnings Snapshot GCO	31/05	AQ
Earnings Flash (GCO) GENESCO Posts Q1 Revenue $457.6M, vs. Street Est of $445.7M GCO	31/05	MT
Genesco Inc. Reports Fiscal 2025 First Quarter Results GCO	31/05	BU
Genesco Inc. Reaffirms Earnings Guidance for the Year 2025 GCO	31/05	CI
Morgan Stanley Boosts Price Target on Ambarella to $67 From $57, Keeps Overweight Rating AMBA	31/05	MT
Morgan Stanley Raises Price Target on Foot Locker to $24 From $20, Maintains Equalweight Rating FL	31/05	MT
NMPRC Approves New PNM Energy Resources for 2026 PNM	31/05	PR
RE/MAX : First Quarter 2024 Presentation RMAX	31/05	PU
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results MLAB	31/05	GL
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results MLAB	31/05	AQ
Truist Adjusts Price Target on Cracker Barrel Old Country Store to $46 From $51, Maintains Hold Rating CBRL	31/05	MT
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US VNDA	31/05	MT